# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-098590
Filing Date
2024-08-19
Accepted
2024-08-19 16:36:58
Documents
73
Period of Report
2024-06-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | eldn-20240630.htm iXBRL | 10-Q | 1978895
2 | EX-31.1 | eldn-ex31_1.htm | EX-31.1 | 14339
3 | EX-31.2 | eldn-ex31_2.htm | EX-31.2 | 14597
4 | EX-32.1 | eldn-ex32_1.htm | EX-32.1 | 9129
5 | EX-32.2 | eldn-ex32_2.htm | EX-32.2 | 9191
| Complete submission text file | 0000950170-24-098590.txt |  | 8712439

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | eldn-20240630.xsd | EX-101.SCH | 1159950
75 | EXTRACTED XBRL INSTANCE DOCUMENT | eldn-20240630_htm.xml | XML | 1583622

Mailing Address 19800 MACARTHUR BLVD. SUITE 250 IRVINE CA 92612
Business Address 19800 MACARTHUR BLVD. SUITE 250 IRVINE CA 92612 949-238-8090
Eledon Pharmaceuticals, Inc. (Filer) CIK: 0001404281 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36620 | Film No.: 241221145
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)